Oral Session: Biological Biomarkers of psychopathology (ESs=0. 13-0.30 Background: Response to treatment in psychotic disorders is highly variable, and biomarkers of treatment response have been lacking to date. As a result, trial and error remains the basis for care in early psychosis and poor outcomes continue to be common in individuals even when duration of untreated psychosis is relatively short and specialized clinical care is provided. Early identification of patients who are less likely to have good treatment responses would help identify individuals who would benefit from alternative and/or supplemental interventions. Here we evaluated the ability of functional magnetic resonance imaging (fMRI)-based measures of cognitive control related brain activity collected during initial engagement in treatment to predict symptomatic improvement in early psychosis patients after one year. Methods: Patients with either schizophrenia (n = 65, 49M/16F, mean age 20.8 years) or Type I bipolar disorder with psychotic features (n = 17, 9M/8F, mean age 21.6 years) were scanned during the AX CPT task at the beginning of treatment and re-evaluated clinically after 12 months of early psychosis specialty care. 138 healthy controls were included to confirm the AX-CPT was activating frontoparietal networks. Patients were classified as Improvers (> 20% improvement on Brief Psychiatric Rating Scale (BPRS) Total Score at one-year follow-up vs. baseline) or Non-Improvers. Behavioral and functional measures of proactive control during the AX-CPT as well as baseline clinical syndrome scores (Reality Distortion (from BPRS/SAPS), Disorganization (from BPRS/SAPS), Poverty from BPRS/SANS) were evaluated on their ability to predict Improver status. Results: Cognitive control-associated measures significantly predicted Improver status (2. = 9.5, p < 0.01) with 70% positive predictive value, 60% negative predictive value, and 66% accuracy. Only the fMRI-based measure (and not the behavioral measure) significantly predicted status. The addition of syndrome scores did not significantly improve model fit (step 2 = 4.5, p = 0.21), although adding these scores increase accuracy to 70% with 75% positive predictive value and 63% negative predictive value. Discussion: Baseline fMRI data significantly predicted clinical improvement after one year of treatment. Although higher rates of prediction should be pursued, this represents an advance over the limited ability of clinicians to predict treatment response in first-episode patients entering care. fMRI may have potential utility in personalized medicine, as treating patients that present with low frontoparietal activation by specialized interventions (e.g. prefrontal brain stimulation) may improve outcome. Future studies may seek to improve predictive power by combining fMRI with other pathophysiologically relevant neuroimaging measures.
O10.7. SIMILARLY ALTERED PROTEIN MARKERS IN DRUG-NAÏVE FIRST-EPISODE
Background: Traditionally, schizophrenia and major depressive disorder (MDD) are seen as separate disorders based on their distinct clinical presentation. In clinical practice however, overlapping symptoms are noticeable such as psychotic symptoms, apathy and cognitive decline. Schizophrenia and MDD are both associated with increased risks of immune disorders and metabolic syndrome. However, it is unclear whether dysfunctions in growth factors, the immune and metabolic system underlie the psychopathology of both schizophrenia and MDD without the influence of chronic illness and treatment. In this meta-analysis we aimed to answer the following question: which peripheral growth, immune and glucose metabolism proteins are similarly altered in drug-naïve first-episode patients with either schizophrenia or MDD compared with healthy controls? Methods: We conducted a meta-analysis of studies providing serum or plasma measurements (in mean and standard deviation) of peripheral protein markers regarding growth, immune and glucose metabolism proteins in drug-naïve first-episode patients with schizophrenia or MDD and healthy controls. We used a random-effects meta-analysis for which mean differences were quantified with Hedges' g (g). Results: A total of 65 case-control studies were retrieved comprising of 3156 drug-naïve and first-episode schizophrenia patients and 3687 controls, and a total of 29 studies were retrieved comprising of 1077 drug-naïve and first-episode MDD patients and 1405 controls. In schizophrenia patients brain-derived neurotrophic factor (BDNF) (g = -0.80, 95% CI -1.00 to -0.61; P < 0.01) and nerve growth factor (NGF) (g = -3.28, 95% CI -6.35 to -0.21; P = 0.04) were significantly decreased, and interleukin 6 (IL-6) (g = 1.03, 95% CI 0.61 to 1.46; P < 0.01), interleukin 8 (IL-8) (g = 0.65, 95% CI 0.11 to 1.18; P = 0.02), tumor necrosis factor alpha (TNFα) (g = 0.51, 95% CI 0.19 to 0.83; P < 0.01), fasting glucose concentration (g = 0.26, 95% CI 0.08 to 0.44; P < 0.01) and fasting insulin concentration (g = 0.40, 95% CI 0.13 to 0.68; P < 0.01) were all significantly elevated compared with controls. In MDD patients C-reactive protein (CRP) (g = 0.45, 95% CI 0.18 to 0.71; P < 0.01), interleukin 1 beta (IL-1β) (g = 1.52, 95% CI 0.38 to 2.66; P < 0.01), interleukin 2 (IL-2) (g = 4.41, 95% CI 0.13 to 8.69; P = 0.04), IL-6 (g = 0.62, 95% CI 0.17 to 1.06; P < 0.01) and TNFα (g = 1.21, 95% CI 0.57 to 1.85; P < 0.01) were all significantly elevated compared with controls. IL-8 was significantly decreased in MDD patients compared with controls (g = -0.84, 95% CI -1.48 to -0.20; P < 0.01). CRP, IFNγ, IL-1β, IL-2, IL-4, interleukin 10 (IL-10) and monocyte chemoattractant protein-1 (MCP-1) were not significantly altered in schizophrenia patients compared with controls. However, for IL-4 we observed a trend of increased levels in schizophrenia. BDNF, NGF, IFNγ, IL-10, fasting insulin concentration and MCP-1 were not significantly altered in MDD patients compared with controls. However, a similar trend of increased levels of CRP was seen for schizophrenia when compared to MDD, and decreased levels of BDNF and NGF and elevated levels of fasting glucose concentration were seen for MDD when compared to schizophrenia. Discussion: This meta-analysis suggests that dysfunctions in growth, immune and glucose metabolism markers are already present in patients with schizophrenia and MDD from disease onset without the influence of psychotropic treatment. Strikingly, of the 14 proteins identified in this meta-analysis, 10 (71%) are changed in the same direction (trends included) or unchanged in both schizophrenia and MDD. Our findings indicate shared preventive strategies and on-time treatment for immune and metabolic dysfunctions prevalent in these disorders. Downloaded from https://academic.oup.com/schizophreniabulletin/article-abstract/45/Supplement_2/S192/5434202 by guest on 18 September 2019
